Loading...
Loading...
GHRS| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 6,626.0K |
| Operating I/L | -6,626.0K |
| Other Income/Expense | 6,185.0K |
| Interest Income | 0.0K |
| Pretax | -441.0K |
| Income Tax Expense | -6,185.0K |
| Net Income/Loss | 5,744.0K |
GH Research PLC is a clinical-stage biopharmaceutical company specializing in the development of therapies for psychiatric and neurological disorders. The company's primary focus is on the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of treatment-resistant depression (TRD). Their lead program, GH001, is an inhalable 5-MeO-DMT product candidate that has completed Phase 1 and Phase 1/2 clinical trials in TRD patients. Additionally, the company is developing GH002, an injectable 5-MeO-DMT product candidate, and GH003, an intranasal 5-MeO-DMT product candidate, both in preclinical development trials for psychiatric and neurological disorders.
